Pharmaceutical Technology on MSN7d
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating ...
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...
Hosted on MSN9mon
Otsuka and Lundbeck report data from three PTSD treatment trials
Otsuka Pharmaceutical Development & Commercialization and Lundbeck Pharmaceuticals have reported results from three clinical trials evaluating the combination of brexpiprazole and sertraline in ...
PharmaTimes8d
Rxulti approved in the European Union for adolescent schizophrenia
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
The Pharma Letter8d
Rxulti now approved for adolescents in Europe
The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...
Medical Dialogues3d
Alembic Global Holding incorporates wholly-owned subsidiary in USA
Vadodara: Alembic Global Holding SA, a wholly owned subsidiary of Alembic Pharmaceuticals Limited has incorporated a wholly-owned subsidiary in USA, named Alembic Lifesciences Inc.
Finanznachrichten8d
H. Lundbeck A/S: Rxulti (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older 1 Approval follows a positive Committee for Medicinal Products ...